摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

3-甲氧基-4-氨基苯酚 | 61638-01-5

中文名称
3-甲氧基-4-氨基苯酚
中文别名
4-氨基-3-甲氧基苯酚
英文名称
4-Amino-3-methoxyphenol
英文别名
——
3-甲氧基-4-氨基苯酚化学式
CAS
61638-01-5
化学式
C7H9NO2
mdl
——
分子量
139.154
InChiKey
SXJQUUPSLJTKKT-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    210 °C
  • 沸点:
    315.9±27.0 °C(Predicted)
  • 密度:
    1.219±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    0.9
  • 重原子数:
    10
  • 可旋转键数:
    1
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.14
  • 拓扑面积:
    55.5
  • 氢给体数:
    2
  • 氢受体数:
    3

安全信息

  • 海关编码:
    2922509090
  • 危险性防范说明:
    P305+P351+P338
  • 危险性描述:
    H302,H315,H319
  • 储存条件:
    室温和干燥环境下使用。

SDS

SDS:dc87698cc541b8c26f3680df8eadd630
查看
Material Safety Data Sheet

Section 1. Identification of the substance
Product Name: 4-Amino-3-methoxyphenol
Synonyms:

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

Section 3. Composition/information on ingredients.
Ingredient name: 4-Amino-3-methoxyphenol
CAS number: 61638-01-5

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels, refrigerated.
Storage:

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C7H9NO2
Molecular weight: 139.2

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

Section 11. Toxicological information
No data.

Section 12. Ecological information
No data.

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

Section 14. Transportation information
Non-harzardous for air and ground transportation.

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.


SECTION 16 - ADDITIONAL INFORMATION
N/A

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    参考文献:
    名称:
    Reversible Inhibitors of the Gastric (H+/K+)-ATPase. 4. Identification of an Inhibitor with an Intermediate Duration of Action
    摘要:
    3-Acyl-4-(arylamino)quinolines were previously identified as gastric (H+/K+)-ATPase inhibitors, and clinical efficacy has been demonstrated for compound 3 (SK&F 96067). In the present study the further structure-activity relationship of this series is developed. Only a limited range of substituents are tolerated on the N-aryl ring or the 6- and 7-positions of the quinoline, and although hydroxylated derivatives were identified possessing markedly greater affinity for the enzyme, none of these proved to have adequate potency after oral dosing. In contrast, the 8-position of the quinoline ring proved suitable for a wide variety of substituents, allowing modification of physicochemical properties while retaining primary activity. This led to the identification of compound 4 (SK&F 97574), which combines good oral potency with a somewhat longer duration of action than 3 (though much shorter than covalent inhibitors such as omeprazole). This compound was selected for further development and evaluation in man.
    DOI:
    10.1021/jm00014a026
  • 作为产物:
    描述:
    参考文献:
    名称:
    Reduction of aryl nitro compounds
    摘要:
    公开号:
    US02198249A1
点击查看最新优质反应信息

文献信息

  • [EN] COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASE 1 PROTEINS<br/>[FR] COMPOSÉS ET PROCÉDÉS POUR LA DÉGRADATION CIBLÉE DE PROTÉINES DE KINASE 1 ASSOCIÉS AU RÉCEPTEUR DE L'INTERLEUKINE 1
    申请人:JANSSEN PHARMACEUTICA NV
    公开号:WO2021018118A1
    公开(公告)日:2021-02-04
    The present invention relates to compounds comprising an interleukin-1 receptor-associated kinase 1 (IRAK1) protein binding moiety and a Von Hippel-Lindau (VHL) E3 ubiquitin ligase binding moiety, and associated methods of use. The compounds are useful as modulators of targeted ubiquitination, especially with respect to IRAK1, which is degraded by the compounds according to the invention.
    本发明涉及包含白细胞介素-1受体相关激酶1(IRAK1)蛋白结合基团和Von Hippel-Lindau(VHL)E3泛素连接酶结合基团的化合物,以及相关的使用方法。这些化合物可用作靶向泛素化的调节剂,特别是在与根据本发明降解的IRAK1相关的情况下。
  • Novel pyridine derivative and pyrimidine derivative
    申请人:Matsushima Tomohiro
    公开号:US20050277652A1
    公开(公告)日:2005-12-15
    A compound represented by the following formula, a salt thereof or a hydrate of the foregoing has an excellent hepatocyte growth factor receptor (HGFR) inhibitory activity, and exhibits anti-tumor activity, angiogenesis inhibitory activity and cancer metastasis inhibitory activity. [R 1 represents C 1-6 alkyl or the like; R 2 and R 3 represent hydrogen; R 4 , R 5 , R 6 , and R 7 may be the same or different and each represents hydrogen, halogen, C 1-6 alkyl or the like; R 8 represents hydrogen or the like; R 9 represents C 1-6 alkyl or the like; V 1 represents oxygen or the like; V 2 represents oxygen or sulfur; W represents —NH— or the like; X represents —CH═, nitrogen or the like; and Y represents oxygen or the like.]
    以下化合物的分子式,其盐或前述水合物具有出色的肝细胞生长因子受体(HGFR)抑制活性,并表现出抗肿瘤活性、抑制血管生成活性和抑制癌转移活性。 [R 1 代表C 1-6 烷基或类似物;R 2 和R 3 代表氢;R 4 ,R 5 ,R 6 和R 7 可以相同也可以不同,每个代表氢、卤素、C 1-6 烷基或类似物;R 8 代表氢或类似物;R 9 代表C 1-6 烷基或类似物;V 1 代表氧或类似物;V 2 代表氧或硫;W代表—NH—或类似物;X代表—CH═、氮或类似物;Y代表氧或类似物。]
  • Optimization of the Azobenzene Scaffold for Reductive Cleavage by Dithionite; Development of an Azobenzene Cleavable Linker for Proteomic Applications
    作者:Geoffray Leriche、Ghyslain Budin、Laurent Brino、Alain Wagner
    DOI:10.1002/ejoc.201000546
    日期:——
    henylazo)benzoic acid (HAZA) scaffold, the orthogonally protected difunctional azo–arene cleavable linker 26 was designed and synthesized. Selective linker deprotection and derivatization was performed by introducing an alkyne reactive group and a biotin affinity tag. This optimized azo–arene cleavable linker led to a total cleavage in less than 10 s with only 1 mM dithionite. Similar results were
    在本文中,我们进行了广泛的反应性研究,以确定有利于连二亚硫酸盐引发的偶氮芳烃基团还原裂解的关键结构特征。我们的逐步研究允许鉴定在缺电子芳烃的邻位带有羧酸的高反应性偶氮芳烃结构 25 和作为富电子芳烃的邻位-O-烷基间苯二酚。基于这种 2-(2'-烷氧基-4'-羟基苯基偶氮)苯甲酸 (HAZA) 支架,设计并合成了正交保护的双功能偶氮芳烃可裂解接头 26。通过引入炔反应基团和生物素亲和标签来进行选择性接头脱保护和衍生化。这种优化的偶氮芳烃可裂解接头导致在不到 10 秒内完全裂解,仅含 1 mM 连二亚硫酸盐。
  • [EN] COMPOUNDS FOR INHIBITING TNIK AND MEDICAL USES THEREOF<br/>[FR] COMPOSÉS DESTINÉS À L'INHIBITION DE TNIK ET UTILISATIONS MÉDICALES ASSOCIÉES
    申请人:KOREA RES INST CHEMICAL TECH
    公开号:WO2019156439A1
    公开(公告)日:2019-08-15
    The present disclosure provides the compound having inhibitory property against TNIK having a specific chemical structure or its pharmaceutically acceptable salt. The present disclosure also provides a composition comprising the compound or its pharmaceutically acceptable salt. The present disclosure also provides a medical use of the compound, its salt or the composition comprising the compound or its pharmaceutically acceptable salt for treating or preventing cancer. The present disclosure also provides a method of treatment or prevention of cancer comprising administering the compound, its salt or the composition comprising the compound or its salt to a subject in need of such treatment or prevention.
    本公开提供了具有抑制TNIK活性的化合物,其具有特定化学结构或其药用可接受盐。本公开还提供了包含该化合物或其药用可接受盐的组合物。本公开还提供了该化合物、其盐或包含该化合物或其药用可接受盐的组合物的医疗用途,用于治疗或预防癌症。本公开还提供了一种治疗或预防癌症的方法,包括向需要此类治疗或预防的受试者施用该化合物、其盐或包含该化合物或其盐的组合物。
  • Fused ring 4-oxopyrimidine derivative
    申请人:Nagase Tsuyoshi
    公开号:US20050182045A1
    公开(公告)日:2005-08-18
    The present invention provides a compound represented by formula (I) below, or a pharmaceutically acceptable salt thereof, which, having histamine H3 receptor antagonist or inverse agonist activity, is useful in the prophylaxis or therapy of metabolic diseases, circulatory diseases, or nervous system diseases. [where, for example, Ar is a divalent group formed by eliminating two hydrogen atoms from benzene, X 1 is a nitrogen atom, sulfur atom or oxygen atom, R 1 is a 5- to 6-membered heteroaryl group, Ring A is a 5- to 6-membered heteroaryl ring, R 2 and R 3 are amino groups or alkylamino groups, and X 2 is represented by formula (II): (where R 4 and R 5 are lower alkyl groups, and n is an integer from 2 to 4).]
    本发明提供以下公式(I)所表示的化合物或其药学上可接受的盐,具有组织胺H3受体拮抗剂或逆激动剂活性,在代谢性疾病、循环系统疾病或神经系统疾病的预防或治疗中有用。【其中,例如,Ar是通过从苯中消除两个氢原子形成的二价基团,X1是氮原子、硫原子或氧原子,R1是5-至6-成员杂芳基团,环A是5-至6-成员杂芳基环,R2和R3是氨基或烷基氨基,X2由以下公式(II)表示:(其中R4和R5是较低烷基基团,n是从2到4的整数)。】
查看更多